PuraMed BioScience, Achieves Six-Month Goals with NACDS and Kicks Off the Second Half of 2012 with Aggressive LipiGesic&#0174 M Awareness and Sales Campaigns Nationwide

SCHOFIELD, Wis., July 17, 2012 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB:PMBS) attended the National Association of Chain Drug Stores' (NACDS) Marketplace 2012 held in Denver Colorado between June 23- 26 to complete the company's key goals for the first half of 2012.

"We have accomplished all the goals that we set for PuraMed BioScience during the first half of the year," said Russ Mitchell, president and CEO of PuraMed BioScience. "Most notably, we achieved placement of LipiGesic M in Walgreens and CVS/pharmacy stores, which represents approximately 15,000 locations nationwide.

"In addition, we ramped up advertising in major newspapers and trade journals across the country; launched radio campaigns in the southwest region of the nation that yielded impressive results; initiated a clinical trial for children and adolescents with key migraine researchers; created in-store video displays; attended major medical and pharmaceutical shows; and provided samples to over 1,000 health care providers during the first six months of 2012.

"With our attendance at the NACDS Marketplace, we were able to personally speak to over 40 key decision makers in the wholesale and retail pharmaceutical industry," said Mitchell. "The NACDS Marketplace 2012 was the best venue to build awareness and relationships as we plan future distribution of LipiGesic® M, our clinically-tested migraine treatment product."

PuraMed BioScience also executed a trade-based advertising campaign to coincide with the NACDS event. Several trade magazines such as Chain Drug Review, Mass Market Retailer and Pharmacy Times offered value-added program components that included an expanded company profile or product sampling as well as bonus distribution of the publication at the NACDS Marketplace.

"There was definitely a high level of interest by the mass marketers and wholesalers," said Mitchell. "With the recent recalls in the OTC migraine category, we have a great opportunity to fill the needs of both the retailer and the customer. Buyer interest confirmed that we are on the right track."

LipiGesic M is a natural, homeopathic formulation of feverfew and ginger suspended in a pharmaceutical-grade gel that is administered sublingually (under the tongue). This formulation and delivery method allows the full-strength ingredients to reach the bloodstream quickly.

"Users often report that they can feel pain relief and relief of associated symptoms, such as auras, start in minutes," said Mitchell. "Many of these people are skeptical at first because they have tried other OTC and prescription medications that either do not work for them or cause severe and debilitating side effects. LipiGesic M is fast, safe and effective it doesn't even cause rebound headaches common with migraine medications that contain aspirin or acetaminophen."

PuraMed is currently preparing to launch a comprehensive sales campaign to increase distribution in additional mass market chains and in national wholesalers, as well as introducing LipiGesic M to regional independent pharmacies. "Representatives from these key accounts expressed strong interest in LipiGesic M at the NACDS Marketplace 2012," said Mitchell.

In addition to the aggressive sales campaign, PuraMed's goals for the second half of the year include: the implementation of a large email campaign to a migraine-specific audience in strategically selected areas; an increase in celebrity endorsements on well-known television, radio and Internet programs; increased placement of newspaper and radio advertisements in major cities across the nation; and plans for a large-scale clinical study of LipiGesic M.

"We are also looking forward to the results of the child and adolescent clinical trial," said Mitchell. "We know that LipiGesic M has an excellent safety profile without known drug interactions. This makes it a great choice for people of all ages."

The initial clinical trial results published in the July 2011 issue of Headache: The Journal of Head and Face Pain, a top-tier medical publication, show that LipiGesic M is an effective, first-line treatment for migraine when taken as directed and used at the first sign of headache.

To learn more about this homeopathic migraine product and read the clinical study, visit www.LipiGesic.com.

About the Company:
PuraMed BioScience, Inc., engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic® M, which provides acute relief from migraine headaches; the company also has plans to launch LipiGesic® PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic® H for common tension headaches.

For more information on PuraMed BioScience, visit www.PuraMedBioScience.com, join the company's group page on Facebook by searching "PuraMed BioScience" and follow the company on Twitter at www.twitter.com/puramed.

Forward-Looking Statements:
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

SOURCE PuraMed BioScience, Inc.